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AbstrAct
Objective Treatment of type 1 diabetes has been 
intensified aiming at normalizing blood glucose, which 
may increase the risk of severe hypoglycemia (SH). We 
aimed to compare the incidence of SH events in the four 
Nordic countries Denmark, Iceland, Norway and Sweden, 
and to assess the influence of hemoglobin A1c (HbA
1c
) and 
treatment modalities on the frequency of SH; particularly, 
to explore if a HbA
1c
 target ≤6.7% (50 mmol/mol) is 
feasible.
Research design and methods Data on children below 
15 years with a diabetes duration more than 1 year, 
registered in the national childhood diabetes databases 
in the four Nordic countries from 2008 to 2012, were 
compiled. Data completeness was more than 95%.
Results Totally 8806 (48% females) patients with 29 715 
person years were included, mean age and diabetes 
duration were 11 years and 5.1 years, respectively. The 
overall rate of SH was 6.0 per 100 patient-years, and 
did not change during the study period. The Swedish 
population constantly had the lowest SH incidence while 
it decreased significantly in the Danish population. HbA
1c
 
decreased significantly over time (p<0.01), while the 
number of pump users increased (p<0.01). Stratifying for 
HbA
1c
 levels showed the lowest risk of SH in patients with 
HbA
1c
 ≤6.7% (≤50 mmol/mol), but in the statistical models 
adjusting for possible confounders the difference between 
the HbA
1c
 groups disappeared. Pump users had the lowest 
SH risk, also after adjusting for possible confounders.
Conclusions Risk of SH differs between the Nordic 
countries with the lowest risk in Sweden. Pump therapy 
was associated with decreased risk of SH. The low HbA
1c
 
group had the same or a lower risk of SH compared with 
the highest HbA
1c
 groups. A target HbA
1c
 ≤6.7% (≤50 mmol/
mol) seems achievable without increasing the risk of SH.
IntroductIon
To reduce long-term complications in type 1 
diabetes (T1D) blood glucose (BG) should 
be close to normal.1 Accordingly, the new 
guidelines from the International Society of 
Pediatric and Adolescent Diabetes in 2014 
and the American Diabetes Association 
in 2014 recommend a haemoglobin A1c 
(HbA1c) below 7.5% (58 mmol/mol) in chil-
dren below 18 years.2 3 The National Institute 
for Health and Care Excellence recommend 
a HbA1c level of 6.5% (48 mmol/mol) or 
lower (https://www. nice. org. uk/ guidance/ 
qs125/ chapter/ Quality- statement- 2-Educa-
tion- and- information), and some centres in 
Scandinavia have changed their HbA1c target 
to 6.7% (50 mmol/mol). It is unknown if this 
target level can be obtained without increasing 
the risk of severe hypoglycemia (SH) events. 
Reducing the HbA1c target without increasing 
the SH risk has previously been of opposing 
demands, particularly in young children.1 4 5 
Many children and their parents fear SH, and 
tend to increase mean BG, thereby deterio-
rating metabolic control.6 7 Over the last one 
significance of this study
What is already known about this subject?
 ► The incidence of severe hypoglycemia (SH) in 
children with type 1 diabetes is decreasing, and 
during the last two decades there has been a 
shift from a strong negative association between 
hemoglobin A1c (HbA
1c
) and SH to no association.
What are the new findings?
 ► The incidence of SH differs between the Nordic 
countries despite equal access to healthcare.
 ► Pump therapy is associated with decreased risk of 
SH.
 ► HbA
1c
 below 50 mmol/mol is not a risk factor for SH.
How might these results change the focus of 
research or clinical practice?
 ► Focus should be on causes of differences in SH 
between countries.
 ► The HbA
1c
 target may be reduced to 6.7% (50 mmol/
mol) and below.
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or two decades, insulin treatment regimens have been 
intensified, and treatment modalities have changed 
from regular insulin to analog insulin or continuous 
subcutaneous insulin infusion.8–10 In the same period, an 
increased number of BG measurements and insulin bolus 
injections have been recommended.3 These changes 
may all contribute to reduce the frequency of SH. Thus, 
a report from the German and Austrian ‘Diabetes Pati-
enten Verlaufsdokumentation’ (DPV) database has 
shown a decrease in the relative risk of SH, particularly 
in the groups with the lowest HbA1c,
11 a study from the 
Danish Registry of Childhood and Adolescent Diabetes 
(DanDiabKids) showed a significant decrease in SH in the 
period 2008–2012 with unchanged HbA1c,
9 and a multi-
center and multinational study from the Hvidoere Study 
Group showed significant differences in the frequency 
of SH between diabetes centers in different countries.12 
Finally, a recent multicenter study, including the DPV 
database and large centers from Australia and the USA, 
reported the SH incidence independent of HbA1c,
13 but 
investigations in other large longitudinal cohorts were 
called for. No studies have compared incidence data of 
SH between complete national childhood databases in 
countries with equal access to healthcare.
We aimed to (1) compare the incidence of SH events 
in children with T1D in the four Nordic countries in 
the period 2008–2012 and (2) examine the influence 
of HbA1c and treatment modalities on the frequency of 
SH, and particularly, explore if a HbA1c target ≤6.7% (50 
mmol/mol) is possible without increasing the risk of SH.
reseArch desIgn And methods
Data on children below 15 years of age registered in the 
national childhood diabetes databases in the four Nordic 
countries—Denmark, Iceland, Norway and Sweden—
from 1 January 2008 to 31 December 2012 were compiled. 
All 89 Nordic centers—18 in Denmark, 1 in Iceland, 27 
in Norway, 43 in Sweden—treating T1D in children regis-
tered data in the national databases.14 Only children with 
a diabetes duration of more than 1 year were included. 
Data ascertainment concerning incident cases with the 
diagnosis T1D was 99% in the Danish registry (DanDiab-
Kids), almost 100% in the Icelandic registry, 92%–93% in 
the Norwegian registry for childhood diabetes (Norwe-
gian Childhood Diabetes Registry) and almost 100% in 
the Swedish registry for childhood diabetes (SweDiab-
Kids).9 14 Data completeness of the different variables 
varied between 96% and 99%. HbA1c and SH data 
completeness was 98% and 99%, respectively.
Data on gender, age, diabetes duration, HbA1c, insulin 
dose per kilogram per day, treatment modality, weight, 
height and SH were registered once a year at the visit 
closest to the patient’s date of birth in Denmark and the 
first visit of the year in Norway. In Iceland and Sweden, all 
variables were registered at each visit every third month, 
but data for this study were the last dataset of the year, 
apart from SH and HbA1c. SH events were registered at 
each visit and summed up at the last visit of the year; 
HbA1c for this study was the individual mean of the four 
registrations collected during the year.
HbA1c was measured centrally in Denmark, Iceland and 
Norway, while it was decentralized in Sweden. Denmark 
and Norway used a high-pressure liquid chromato-
graphic method (Tosoh Bioscience, South San Francisco, 
California, USA). In Iceland, HbA1c was measured with 
the DCA 2000 Vantage Analyzer (Siemens AG, Erlangen, 
Germany). In Sweden HbA1c was measured with the 
DCA 2000 Vantage Analyzer, or with local laboratory 
methods.15 All laboratories in the Nordic countries are 
validated through the International Federation of Clin-
ical Chemistry and Laboratory Medicine reference 
program several times a year.15 16
SH was defined in accordance with the guidelines of the 
International Society of Pediatric and Adolescent Diabetes 
as an event associated with severe neuroglycopenia 
resulting in coma or seizure and requiring parenteral 
therapy (glucagon or intravenous glucose).17
Body mass index (BMI) was calculated as weight in kilo-
grams divided by height in square meters, and BMI SD 
score (BMISDS) was calculated from the Swedish popula-
tion-based longitudinal reference values from birth to 18 
years of age for height and weight.18
ethics
The registries in Denmark, Norway, and Sweden have 
national quality registry status. In Denmark, patient 
consent is not required before registration. In Norway, 
parents have to provide written, informed consent. 
Parents and patients in Sweden are informed about the 
registry before agreeing to be included. The Icelandic 
registry has been approved by the National Bioethics 
Committee and the Data Protection Authority. The 
project has been approved by the database steering 
committees in the four countries.
statistical analysis
The dataset consisted of multiple records for each 
patient in the four Nordic countries. The number of 
contributing patient-years was calculated based on time 
from first to last registered visit. For descriptive analysis, 
mean and SD were calculated for continuous variables 
and percentages for categorical variables. Multilevel 
mixed-effects models were used to test if HbA1c (linear 
regression) and treatment (logistic regression) changed 
during the period. The categorical variable calendar 
year was used to assess changes in SH. Predictors of SH 
were identified using univariate and multivariate nega-
tive binomial regression models,19 with country as fixed 
effect and patient as random effect. Three multivariate 
models were tested: model 1, including the independent 
variables gender, age and diabetes duration; model 2, 
model 1 plus the variable year; model 3, model 2 plus 
the variables BMISDS and HbA1c/treatment modality. 
Results are presented as incidence risk ratio with 95% 
CIs. A sensitivity test was conducted excluding patients 
group.bmj.com on November 1, 2017 - Published by http://drc.bmj.com/Downloaded from 
3BMJ Open Diab Res Care 2017;5:e000377. doi:10.1136/bmjdrc-2016-000377
Pathophysiology/Complications
in partial remission defined as an insulin dose <0.4 IU/
kg/day to test a possible impact of endogenous insulin 
production. A two-sided p value <0.05 was considered 
statistically significant. Analyses were performed using 
STATA V.13 and SPSS V.21.
results
A total of 8806 (48% females) patients with T1D dura-
tion of more than 1 year were enrolled into the study, 
resulting in 29 715 person years with 1775 SH events in 
1087 patients. Thus 89.6% of the patients had no SH, 
9.1% had one to two SH and 1.3% had three or more SH. 
Mean age was 11 years and mean diabetes duration was 
5.1 years (table 1). Excluding children with a daily insulin 
dose of less than 0.4 IU/kg did not change the results; 
thus results presented are for the whole cohort.
Incidence of sh over time
The highest incidence of SH was in 2009 with seven SH 
events per 100 patient-years, and the lowest incidence 
was in 2012 with five SH events per 100 patient-years. In 
total, the SH incidence did not change significantly in 
the Nordic countries over the 5-year study period, and 
the total incidence of SH in the whole study period was 
6.0 per 100 patient-years. Comparing the individual 
years, significant variations could be shown. The Swedish 
population had the lowest SH incidence, while the SH 
incidence was stable between 7 and 10 SH events per 100 
patient-years in the Norwegian population. The SH inci-
dence decreased in the Danish population (p<0.01). The 
same decrease was seen as a trend in the Icelandic popu-
lation (figure 1).
hemoglobin A1c
Mean HbA1c decreased significantly during the period 
(p<0.001), primarily caused by a steady decrease in HbA1c 
in the Swedish population, while it was unchanged in 
the other countries. HbA1c was significantly lower in the 
Swedish population (total mean 7.9% (62.3 mmol/mol)) 
throughout the period, compared with total mean HbA1c 
in Denmark 8.1% (65.4 mmol/mol), Norway 8.4% (68.6 
mmol/mol) and Iceland 8.5% (69.4 mmol/mol).
hemoglobin A1c and sh
The incidence of SH was lowest in the group with the 
lowest HbA1c (HbA1c ≤6.7% (≤50 mmol/mol), (p=0.04) 
(table 2). When adjusting for gender, age and diabetes 
duration in the multivariate analysis, there was no 
Table 1 Baseline data based on the treatment data presented
Total group Sweden Denmark Norway Iceland p Value
n (patient-years) 29 715 16 901 5700 6871 243
n (patients) 8806 4138 2150 2438 80
Gender <0.01
  Male 4534 (52%) 2182 (53%) 1051 (49%) 1264 (52%) 37 (47%)
  Female 4270 (48%) 1956 (47%) 1099 (51%) 1174 (48%) 41 (53%)
Age groups <0.01
  0–4 years 273 (3%) 156 (4%) 39 (2%) 75 (3%) 3 (4%)
  5–9 years 1948 (22%) 1111 (27%) 401 (19%) 422 (17%) 14 (17%)
  10–14 years 6585 (75%) 2871 (69%) 1710 (80%) 1941 (80%) 63 (79%)
Treatment <0.01
  Pump 4869 (57%) 1984 (50%) 1244 (61%) 1601 (68%) 40 (51%)
  Pen 3607 (43%) 2003 (50%) 803 (39%) 762 (32%) 39 (49%)
Duration* 5.1 (3.1) 5.1 (3.0) 5.2 (3.2) 5.2 (3.1) 5.1 (3.0) 0.46
HbA
1c
 (mmol/mol)* 65 (13) 61 (11) 67 (13) 71 (14) 70 (10) <0.01
HbA
1c
 (%)* 8.1 (1.2) 7.7 (1.0) 8.2 (1.2) 8.6 (1.3) 8.5 (0.9) <0.01
Insulin dose (IU/kg/day)* 0.89 (0.3) 0.86 (0.3) 0.95 (0.3) 0.89 (0.3) 0.90 (0.3) <0.01
*Mean±1SD.
HbA
1c
, hemoglobin A1c.
Figure 1 Unadjusted severe hypoglycemia (SH) in the four 
countries between 2008 and 2012.
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significant difference in the SH incidence risk ratios 
between the HbA1c groups. However, there was a trend 
towards lower SH incidence risk ratio in the group with 
the lowest HbA1c (p=0.07) (table 3).
Pump therapy
The number of patients on pump therapy increased 
significantly from 39% in 2008 to 59% in 2012 (p<0.001). 
Sweden had the lowest percentage of pump users and 
the lowest increase during the 5 year study period (from 
36% to 51%) while Denmark had the largest increase 
in patients on pump therapy. In 2012, 71% of the 
patients were on pump therapy in Denmark and Norway 
(figure 2).
Pump therapy and sh
Patients on pen therapy had a higher risk of SH compared 
with patients on pump therapy with a risk ratio (95 CI) of 
1.3 (1.1  to 1.5) (p<0.01) (table 2). This was partly caused 
by a significantly lower risk of SH in Danish children on 
pump therapy, and partly by a slightly lower SH risk in 
Swedish children on pump therapy. The lower risk of 
SH in pump users persisted in the multivariate models 
(table 3).
other variables and sh
The incidence of SH was independent of gender and age 
groups 1–4, 5–9 and 10–14 years. The SH risk was inde-
pendent of diabetes duration (table 2). Children with  a 
need of an insulin below 0.6 IU/kg/day had the lowest 
SH risk (table 2).
dIscussIon
In the study period between 2008 and 2012, the total 
incidence of SH among children with T1D in the Nordic 
countries Denmark, Iceland, Norway and Sweden was 
stable despite a significant decrease of the mean HbA1c. 
A large variation in the SH incidence between the coun-
tries was shown with the lowest incidence in Sweden. The 
SH rate was independent of the HbA1c level, although, 
with a tendency to lower SH rate in children with the 
lowest HbA1c. Pump treatment appeared to reduce the 
SH risk ratio. Our results obtained in ‘real life’ T1D care 
indicate that a HbA1c target ≤6.7% (50 mmol/mol) may 
be possible without increasing the risk of SH.
The mean rate of six SH events per 100 patient-years was 
lower than the number reported in a multicenter study 
from the Hvidoere Group in children below 11 years of 
age.12 Two studies, one from an Australian regional child-
hood database, including children with T1D with an age 
below 18 and a multicenter US study including children 
between 6 and 18 years with diabetes duration of more 
than 2 years reported SH incidences comparable to our 
study.20 21 The Australian study demonstrated reduced 
risk of SH in patients 12–18 years on pump treatment,21 
while the US study revealed fewer SH episodes in the 
group with ‘excellent glycemic control’,20 which was 
characterized by more frequent pump use, more BG 
Table 2 Risk ratio of SH with 95% CI and p values for 
different risk factors 
Risk factor
Univariate 
analysis—SH risk 
ratio
95% CI p Value
Gender 1.0 (0.9 to 1.2) 0.91
Age (years)
  0–4 1.1 (0.8 to 1.5) 0.62
  5–9 0.9 (0.8 to 1.1) 0.24
  10–14 1.0
Duration (years)
  1–2 0.8 (0.7 to 1.0) 0.06
  2–3 0.9 (0.7 to 1.1) 0.16
  3–4 1.0 (0.8 to 1.2) 0.99
  4–5 1.0 (0.8 to 1.2) 0.83
  >5 1.0
Year
  2008 1.3 (1.0 to 1.6) 0.02
  2009 1.5 (1.3 to 1.8) <0.01
  2010 1.2 (0.98 to 1.4) 0.07
  2011 1.3 (1.0 to 1.5) 0.02
  2012 1
HbA
1c
 (mmol/mol)
  ≤50 0.7 (0.6 to 0.9) 0.04
  >50−≤60 0.9 (0.7 to 1.0) 0.08
  >60−≤70 1.0
  >70 1.0 (0.9 to 1.2) 0.91
  Treatment
  Pen versus 
pump
1.3 (1.1 to 1.5) <0.01
Insulin dose (IU/kg/
day)
  ≤0.6 0.8 (0.6 to 1.1) 0.07
  >0.6−≤0.8 1.0
  >0.8−≤1.0 1.3 (1.1 to 1.6) <0.01
  >1.0−≤1.2 1.3 (1.1 to 1.6) <0.01
  ≥1.2 1.2 (1.0 to 1.5) 0.09
BMISDS
  ≤ −2 0.8 (0.4 to 1.8) 0.59
  > −2 to ≤−1 0.8 (0.6 to 1.1) 0.16
  >−1 to ≤0 0.8 (0.7 to 0.98) 0.03
  0−≤1 1.0
  >1−<2 1.1 (0.9 to 1.3) 0.25
  ≥2 1.0 (0.8 to 1.3) 0.85
Second column showing results of univariate analyses.
BMISDS, body mass index SD score; HbA
1c
, hemoglobin A1c; SH, 
severe hypoglycemia.
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per day and a lower insulin dose per day. Interestingly, a 
Finish single-center study from the 1990s, including only 
pen-treated patients,22 but also a study from the DPV 
database,11 found lower SH rates than in our study.
There were large unexplained variations in SH 
between the four countries. Particularly in Denmark, a 
large decline in the SH rate could be demonstrated from 
16 per 100 patient-years in 2008 to five in 2012. During 
that period a large increase in patients on pump therapy 
was observed.9 However, the SH rate in Sweden was 
stable and low (between 2 and 5 per 100 patient-years) 
and in Norway the SH rate was stable at a higher level 
(between 7 and 10 per 100 patient-years), despite a lower 
percentage of patients using insulin pump in Sweden 
compared with Denmark and Norway. When analyzed in 
toto, there appeared to be an association between insulin 
pump use and lower rates of SH; however, this association 
was not consistently seen across individual countries nor 
did it explain the variance in rates of sever hypoglycemia 
between countries. Other variables explaining variations 
in SH between countries may be different glucose moni-
toring regimens, including sensor-augmented insulin 
pump with threshold suspend feature,23 24 different 
insulin regimens, including daily insulin dose, ratio 
between long-acting/short acting insulin, use of long-
acting insulin analog,9 number of insulin bolus per day 
and different management guidelines.3 25 Initiatives 
such as quality improvement programs26 may also have 
contributed to reduce the risk of SH in Sweden.
During the period 2008–2012 we observed a significant 
overall reduction in HbA1c levels without any change in 
SH events, but there was a large intercountry variation 
in mean HbA1c. Older studies found a negative associ-
ation between SH incidence and metabolic control.4 5 
The relationship between SH and metabolic control has 
been weaker in studies from recent years,11 21 and a new 
multicenter, multinational study found the SH rate to be 
independent of HbA1c.
13 A recent US multicenter study 
showed lower rates of SH in the patients with HbA1c 
below 7% (53 mmol/mol) compared with patients with 
a HbA1c level of more than 9% (75 mmol/mol).
20 Thus, 
during the last two decades, there has been a shift from 
a strong negative association between HbA1c and SH
4 5 
to nearly no association,11 21 and finally, no association 
between HbA1c and SH as demonstrated in our study and 
the new multicenter study including four countries.13
In accordance with the Australian and the DPV 
study,11 20 we did not find any association between gender 
and SH. We did not find any association between age and 
SH in accordance with the Australian study,21 in contrast 
to the DPV study,11 but the age ranges in the two studies 
were 1–18 years21 and 1–20 years,11 respectively. Chil-
dren with insulin requirement below 0.6 IU/kg/day had 
lower risk of SH, indicating a protective role of residual 
beta cell function or perhaps more physiological insulin 
dosing.27 28
strength of the study
The study population consisted of data on the majority 
of children with T1D in the four Nordic countries in a 
5-year period. Data completeness was high and data 
represented ‘real-life’ T1D care. All four countries had 
comparable healthcare systems and free access to health-
care including technical aids such as insulin pump.
limitations of the study
Despite representatives from the four countries gather at 
an annual conference to harmonize data collection prac-
tice, and one or two national conferences are held every 
year, data collection may not be 100% uniform in the 
Table 3 Risk ratio of SH with 95% CI and p values in the different HbA
1c
 groups and in pen versus pump users
Risk factor
Model 1—SH risk ratio
(95% CI), p Value
Model 2—SH risk ratio
(95% CI), p Value
Model 3—SH risk ratio
(95% CI), p Value
HbA
1c
 (mmol/mol)
  ≤50 0.8 (0.6 to 1.0), p=0.07 0.8 (0.6 to 1.0), p=0.09   0.8 (0.6 to 1.1), p=0.25
  >50−≤60 0.9 (0.7 to 1.0), p=0.13 0.9 (0.8 to 1.0), p=0.14   0.9 (0.8 to 1.1), p=0.31
  >60−≤70 1.0 1.0   1.0
  >70 1.0 (0.9 to 1.2), p=0.95 1.0 (1.0 to 1.2), p=0.90   1.0 (0.9 to 1.2), p=0.93
Treatment
  Pen versus pump 1.3 (1.2 to 1.5), p<0.01 1.3 (1.1 to 1.5), p<0.01   1.3 (1.0 to 1.4), p<0.01
HbA
1c
, hemoglobin A1c; SH, severe hypoglycemia.
Figure 2 Percentage of patients on pump therapy in the 
four countries in the period between 2008 and 2012.
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89 centers. Moreover, some SH events may be forgotten 
although families are generally highly affected by SH 
events. In this study, patient-years are calculated as time 
between first and last registered visit. SH are reported 
retrospectively, also at the first visit. Thus, our approach 
slightly underestimates the patient-years for estimating 
SH incidence, and thus slightly overestimates the SH inci-
dence. Data completeness concerning number of BG per 
day and bolus of insulin per day, bolus/basal insulin ratio 
and physical activity, all factors that may impact on the SH 
rate was too low to be useful. Due to sample size differ-
ences, the Swedish results have a much higher impact on 
the total data material than results from Iceland.
conclusIon
The total incidence of SH in the Nordic countries 
remained stable in spite of a significant decrease in HbA1c 
in the period 2008–2012. Although all the four countries 
offer equal access to healthcare, the incidence of SH and 
HbA1c varied. The low incidence of SH in pump users 
compared with pen users and the low incidence of SH in 
the Swedish population warrants further examinations. A 
target HbA1c ≤6.7% (≤50 mmol/mol) may be achievable 
without increasing the risk of SH.
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